Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Identification of Mechanisms in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy

Trial Profile

Identification of Mechanisms in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deferasirox (Primary) ; Deferoxamine (Primary)
  • Indications Anaemia; Aplastic anaemia; Myelodysplastic syndromes; Myelofibrosis
  • Focus Pharmacodynamics
  • Acronyms BIOFER12
  • Most Recent Events

    • 29 Jul 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 21 Jun 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
    • 21 Jun 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top